468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status

• Sheng Yao,
• Sruthi Ravindranathan,
• Theresa LaVallee,
• Sanjay D Khare,
• Narendiran Rajasekaran,
• Patricia Keegan,
• Xiaoguang Wang,
• Daniel J Chin,
• Su-Yi Tseng,
• Scott Klakamp,
• Kate Widmann,
• Varun Kapoor,
• Vladimir Vexler

Affiliations

Sheng Yao

3TopAlliance Biosciences, Inc., Rockville, USA

Sruthi Ravindranathan

1Emory University, Tucker, GA, USA

Theresa LaVallee

5 Coherus Biosciences, Redwood City, California, USA

Sanjay D Khare

Aff1 ImmunGene, Inc. Camarillo CA USA

Narendiran Rajasekaran

Aff1 grid.168010.e0000000419368956Stanford University Stanford CA USA

Patricia Keegan

3TopAlliance Biosciences, Inc., Rockville, USA

Xiaoguang Wang

17 Department of General Surgery, Jiaxing Second People’s Hospital, Jiaxing, China

Daniel J Chin

2Coherus Biosciences, Redwood City, CA, USA

Su-Yi Tseng

2Coherus Biosciences, Redwood City, CA, USA

Scott Klakamp

1Coherus Biosciences, Camarillo, CA, USA

Kate Widmann

1Coherus Biosciences, Camarillo, CA, USA

Varun Kapoor

2Coherus Biosciences, Redwood City, CA, USA

Vladimir Vexler

2Coherus Biosciences, Redwood City, CA, USA